<?xml version="1.0" encoding="utf-8"?>
<oembed>
  <version>1</version>
  <type>rich</type>
  <provider_name>Libsyn</provider_name>
  <provider_url>https://www.libsyn.com</provider_url>
  <height>90</height>
  <width>600</width>
  <title>Journal highlights with Dr. David Henry: Managing hematologic conditions in pregnancy, combo for elderly AML, genomics in DLBCL, and COVID-19 updates</title>
  <description>In this episode, host David H. Henry, MD, highlights some recent articles from Blood, the Journal of Clinical Oncology, and the New England Journal of Medicine. Blood  How I Treat series on hematologic complications in pregnancy. https://bit.ly/3fr5nV8 Mutational and phenotypic characterization of hereditary hemorrhagic telangiectasia. https://bit.ly/3nQvhF6  Journal of Clinical Oncology  Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. https://bit.ly/3maTOE4  Related Blood &amp;amp;amp; Cancer episode: Cancer and hepatitis B virus: ASCO's recommendations for HBV screening, monitoring for reactivation, and how to treat patients. https://bit.ly/3m0jjrF   Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy. https://bit.ly/372FFCB Chemotherapy and COVID-19 Outcomes in Patients With Cancer. https://bit.ly/35WRLOi  Related Blood &amp;amp;amp; Cancer episodes: Studying cancer patients with COVID-19: NCCAPS and CCC19. https://bit.ly/3pYl2Au TERAVOLT registry sheds light on patients with thoracic cancers and COVID-19. https://bit.ly/2URdwJh   Diffuse Large B-Cell Lymphoma’s New Genomics: The Bridge and the Chasm. https://bit.ly/36XdGnY  New England Journal of Medicine  Osimertinib in Resected EGFR-Mutated Non–Small Cell Lung Cancer. https://bit.ly/2J5q7FQ Humoral Immune Response to SARS-CoV-2 in Iceland. https://bit.ly/2USw7ET Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. https://bit.ly/39aM0ia Remdesivir for the Treatment of COVID-19 – Final Report. https://bit.ly/375dYJk Remdesivir for 5 or 10 Days in Patients with Severe COVID-19. https://bit.ly/2IZJ7Wq  Disclosures: Dr. Henry has no relevant disclosures. *&amp;amp;nbsp; *&amp;amp;nbsp; * For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgehemonc David Henry on Twitter: @davidhenrymd </description>
  <author_name>Blood &amp;amp; Cancer</author_name>
  <author_url>https://www.mdedge.com/podcasts/blood-cancer</author_url>
  <html>&lt;iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/16924649/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/984545/" height="90" width="600" scrolling="no"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen&gt;&lt;/iframe&gt;</html>
  <thumbnail_url>https://assets.libsyn.com/secure/item/16924649</thumbnail_url>
</oembed>
